LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
- Disease/Condition
- Diabetes,Diabetes Mellitus, Type 2
- Drug/Device/Intervention
- liraglutide
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Novo Nordisk A/S
- Location
- Birmingham,Montgomery,Tucson,Lancaster,Northridge,Sacramento,San Diego,San Ramon,Vista,Gainesville,Hollywood,Jacksonville,Jacksonville,Jacksonville,Maitland,Miami Lakes,Miami,Miami,Tampa,Lawrenceville, Brazil,India,Israel,Puerto Rico,Russian Federation,United Arab Emirates,United States of America
- Phase
- Phase 3
- Start date
- Mar 03, 2017
- End date
- May 08, 2018
- Enrollment
- 303 participants
Change in HbA1c
The trial is conducted in Asia, Europe, North America and South America. The aim of the study
 is to compare the effect of liraglutide 1.8 mg/day versus placebo as add-on to an SGLT2
 inhibitor with or without metformin on glycaemic control in subjects with type 2 diabetes
 mellitus.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT02964247
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT02964247 through Pure Global AI's free database. This Phase 3 trial is sponsored by Novo Nordisk A/S and is currently Completed. The study focuses on Diabetes,Diabetes Mellitus, Type 2. Target enrollment is 303 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.